FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973356978> ?p ?o ?g. }

• W1973356978 endingPage "1846" @default.
• W1973356978 startingPage "1838" @default.
• W1973356978 abstract "Abstract Objective Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitrogen‐containing bisphosphonate, can be administered using extended dosing intervals, either orally or by rapid intravenous injection. The aim of this study was to identify the optimal intravenous dosing regimen for ibandronate in postmenopausal women with osteoporosis. Methods In a randomized, double‐blind, double‐dummy, phase III, noninferiority study, we compared 2 regimens of intermittent intravenous injections of ibandronate (2 mg every 2 months and 3 mg every 3 months) with a regimen of 2.5 mg of oral ibandronate daily, the latter of which has proven antifracture efficacy. The study group comprised 1,395 women (ages 55–80 years) who were at least 5 years postmenopausal. All patients had osteoporosis (lumbar spine [L2−L4] bone mineral density [BMD] T score less than −2.5). Participants also received daily calcium (500 mg) and vitamin D (400 IU). The primary end point was change from baseline in lumbar spine BMD at 1 year. Changes in hip BMD and in the level of serum C‐telopeptide of type I collagen (CTX) were also measured, as were safety and tolerability. Results At 1 year, mean lumbar spine BMD increases were as follows: 5.1% among 353 patients receiving 2 mg of ibandronate every 2 months, 4.8% among 365 patients receiving 3 mg of ibandronate every 3 months, and 3.8% among 377 patients receiving 2.5 mg of oral ibandronate daily. Both of the intravenous regimens not only were noninferior, but also were superior ( P < 0.001) to the oral regimen. Hip BMD increases (at all sites) were also greater in the groups receiving medication intravenously than in the group receiving ibandronate orally. Robust decreases in the serum CTX level were observed in all arms of the study. Both of the intravenous regimens were well tolerated and did not compromise renal function. Conclusion As assessed by BMD, intravenous injections of ibandronate (2 mg every 2 months or 3 mg every 3 months) are at least as effective as the regimen of 2.5 mg orally daily, which has proven antifracture efficacy, and are well tolerated." @default.
• W1973356978 created "2016-06-24" @default.
• W1973356978 creator A5005612011 @default.
• W1973356978 creator A5013115644 @default.
• W1973356978 creator A5013752581 @default.
• W1973356978 creator A5016379322 @default.
• W1973356978 creator A5021172865 @default.
• W1973356978 creator A5031825241 @default.
• W1973356978 creator A5037951444 @default.
• W1973356978 creator A5039644796 @default.
• W1973356978 creator A5044252195 @default.
• W1973356978 creator A5045290077 @default.
• W1973356978 creator A5050173865 @default.
• W1973356978 creator A5052478195 @default.
• W1973356978 creator A5053097964 @default.
• W1973356978 creator A5066068725 @default.
• W1973356978 creator A5071132796 @default.
• W1973356978 creator A5079796077 @default.
• W1973356978 date "2006-05-25" @default.
• W1973356978 modified "2023-10-17" @default.
• W1973356978 title "Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study" @default.
• W1973356978 cites W1526826623 @default.
• W1973356978 cites W1550111394 @default.
• W1973356978 cites W1967678736 @default.
• W1973356978 cites W1971046106 @default.
• W1973356978 cites W1995580211 @default.
• W1973356978 cites W1997629391 @default.
• W1973356978 cites W1999949526 @default.
• W1973356978 cites W2011470894 @default.
• W1973356978 cites W2012291531 @default.
• W1973356978 cites W2024412436 @default.
• W1973356978 cites W2055031484 @default.
• W1973356978 cites W2055035482 @default.
• W1973356978 cites W2057332307 @default.
• W1973356978 cites W2067177940 @default.
• W1973356978 cites W2069802420 @default.
• W1973356978 cites W2087929119 @default.
• W1973356978 cites W2099054178 @default.
• W1973356978 cites W2102123887 @default.
• W1973356978 cites W2124527463 @default.
• W1973356978 cites W2145594868 @default.
• W1973356978 cites W2150410663 @default.
• W1973356978 cites W2153009489 @default.
• W1973356978 cites W2156015681 @default.
• W1973356978 cites W2401709656 @default.
• W1973356978 doi "https://doi.org/10.1002/art.21918" @default.
• W1973356978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16729277" @default.
• W1973356978 hasPublicationYear "2006" @default.
• W1973356978 type Work @default.
• W1973356978 sameAs 1973356978 @default.
• W1973356978 citedByCount "245" @default.
• W1973356978 countsByYear W19733569782012 @default.
• W1973356978 countsByYear W19733569782013 @default.
• W1973356978 countsByYear W19733569782014 @default.
• W1973356978 countsByYear W19733569782015 @default.
• W1973356978 countsByYear W19733569782016 @default.
• W1973356978 countsByYear W19733569782017 @default.
• W1973356978 countsByYear W19733569782018 @default.
• W1973356978 countsByYear W19733569782019 @default.
• W1973356978 countsByYear W19733569782020 @default.
• W1973356978 countsByYear W19733569782021 @default.
• W1973356978 countsByYear W19733569782022 @default.
• W1973356978 countsByYear W19733569782023 @default.
• W1973356978 crossrefType "journal-article" @default.
• W1973356978 hasAuthorship W1973356978A5005612011 @default.
• W1973356978 hasAuthorship W1973356978A5013115644 @default.
• W1973356978 hasAuthorship W1973356978A5013752581 @default.
• W1973356978 hasAuthorship W1973356978A5016379322 @default.
• W1973356978 hasAuthorship W1973356978A5021172865 @default.
• W1973356978 hasAuthorship W1973356978A5031825241 @default.
• W1973356978 hasAuthorship W1973356978A5037951444 @default.
• W1973356978 hasAuthorship W1973356978A5039644796 @default.
• W1973356978 hasAuthorship W1973356978A5044252195 @default.
• W1973356978 hasAuthorship W1973356978A5045290077 @default.
• W1973356978 hasAuthorship W1973356978A5050173865 @default.
• W1973356978 hasAuthorship W1973356978A5052478195 @default.
• W1973356978 hasAuthorship W1973356978A5053097964 @default.
• W1973356978 hasAuthorship W1973356978A5066068725 @default.
• W1973356978 hasAuthorship W1973356978A5071132796 @default.
• W1973356978 hasAuthorship W1973356978A5079796077 @default.
• W1973356978 hasBestOaLocation W19733569781 @default.
• W1973356978 hasConcept C125870589 @default.
• W1973356978 hasConcept C126322002 @default.
• W1973356978 hasConcept C126894567 @default.
• W1973356978 hasConcept C131075544 @default.
• W1973356978 hasConcept C141071460 @default.
• W1973356978 hasConcept C160160445 @default.
• W1973356978 hasConcept C181199279 @default.
• W1973356978 hasConcept C185592680 @default.
• W1973356978 hasConcept C197934379 @default.
• W1973356978 hasConcept C2776541429 @default.
• W1973356978 hasConcept C2776886416 @default.
• W1973356978 hasConcept C2777251235 @default.
• W1973356978 hasConcept C2777288759 @default.
• W1973356978 hasConcept C2778375690 @default.
• W1973356978 hasConcept C2779329777 @default.
• W1973356978 hasConcept C2781413609 @default.
• W1973356978 hasConcept C55493867 @default.

• next